Advertisement Cambridge China Centre
Advertisement: Mogrify
Mid banner advertisement: BDO
Advertisement: RSM
RealVNC mid-banner general
Advertisement EY mid banner
Barr Ellison Solicitors – commercial property
ARM Innovation Hub
Advertisement: Bradfield Centre mid
Advertisement: Cambridge Network
RealVNC mid banner careers
16 April, 2019 - 14:16 By Kate Sweeney

Inivata enhances personalised cancer medicine drive

Inivata CEO Clive Morris

A UK mission to maintain a world lead in the delivery of personalised medicine to treat cancer has been enhanced by a successful first phase of liquid biopsy and allied technology from a Cambridge business and its US partner.

Genomics England has announced the successful completion of the first phase of its collaboration with Inivata and Thermo Fisher Scientific. It forms part of a pilot project undertaken by Genomics England in collaboration with industry.

Inivata and Thermo Fisher Scientific analysed around 200 blood plasma samples donated by participants of the 100,000 Genomes Project for their suitability for Next Generation Sequencing-based testing. 

The analysis also served to further establish the capacity of Inivata’s liquid biopsy platform, InVision®, and Thermo Fisher Scientific’s Oncomine™ Pan-Cancer Cell-Free Assay to identify the presence of cancer.

The results of the study showed that the plasma samples collected were of a high quality and produced reliable results when analysed. These results were consistent across all cancer types.

The collection methods were shown to allow for ctDNA analysis, opening up a range of possibilities for the further analysis of banked samples using liquid biopsy technology such as those provided by Inivata and Thermo Fisher Scientific. This demonstrates the strong potential for liquid biopsy to improve cancer management and outcomes for UK patients.

These results, and those from the two subsequent phases, will be shared with researchers in the UK and around the world providing additional multiomic data to members of the Genomics England Clinical Interpretation Partnership (GeCIP) and Discovery Forum.

The second phase of the study aims to generate data to form the basis of an objective technology assessment between pre-selected liquid biopsy companies. This will inform future procurement and research strategies to improve patient outcomes. 

The final phase will be a proof of concept longitudinal ctDNA sample study. This will help develop less invasive sample collection techniques, more effective monitoring processes, and ultimately better cancer care.

Clive Morris, CEO at Inivata, said: “We are delighted to be working with Genomics England and to see the progress being made with this collaborative study. 

“The successful end of this initial phase demonstrates the quality of the sample collection from all sites and will enable the exploration of a number of ways of providing further insights to patients. 

“Inivata and Genomics England share a commitment to delivering innovations to UK patients, unlocking exciting new treatment options and improving patient care.”

Joanne Hackett, chief commercial officer at Genomics England, said that exploring new and developing technologies was central to the mission at Genomics England.

“If we are to keep the UK a world leader in the delivery of genomic medicine, it is going to be through collaborations such as this with leading technology companies.”

Newsletter Subscription

Stay informed of the latest news and features